Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Iranian Journal of Public Health. 2012; 41 (6): 93-96
in English | IMEMR | ID: emr-124851

ABSTRACT

Trichophyton verrucosum is a zoophilic fungus with a worldwide distribution. Our aim was to investigate the proliferative effect of antigenic compounds of T. verrucosum on dermis fibro blasts and endothelial cells. T. verrucosum was cultured in SCC medium and was then transferred to a broth medium. Surface antigens of this fungus were separated using the freeze and thaw method. The sample was centrifuged and the supernatant was taken. The supernatant was homogenized and purified. The prepared antigenic extract was added to fibro blast cell lines according to a regular timetable. Cytotoxicity and cell proliferation were evaluated using zymography and densitometry in order to assay MMPs activity. Statistical analyses showed that this antigenic extract is able to enhance the MMPs activity. Trichophyton verrucosum increases the proliferation of dermis germinal layer and MMP-2 activity, which has a direct relation with wound healing process


Subject(s)
Fibroblasts , Matrix Metalloproteinases , Antigens, Surface , Cell Proliferation , Cytotoxicity, Immunologic , Wound Healing
2.
Bina Journal of Ophthalmology. 2009; 14 (4): 413-419
in Persian | IMEMR | ID: emr-165197

ABSTRACT

To compare the efficacy of granisetron, metoclopramide and dexamethasone in prevention of post operative nausea and vomiting [PONV] after cataract surgery. Sixty patients scheduled for cataract surgery with age between 45 to 80 years and with ASA class I and II were enrolled in this clinical trial. The patients were randomly allocated to three 20- person groups. The induction of anesthesia in all groups was similar using the same drugs. Granisetron 1 mg IV was administered to patients in the first group and metoclopramide 0.2 mg/kg/IV [Max: 10 mg] was administered to the second group at the end of the surgery. In the third group dexamethasone 0.15 mg/kg/IV [Max: 8 mg] was used before surgery. Patients in all three groups were observed for PONV at defined intervals for 24 hours. Incidence of PONV during first 6 hours after surgery was 5% in granisetron group, 35% in metoclopramide group and 15% in dexamethasone group. Only the difference between granisetron and metoclopramide groups was statistically significant [P= 0.01]. Incidence of late PONV [6-24 h] was 5% in granisetron group, 30% in metoclopramide group and zero in dexamethasone group. This difference was statistically significant [P<0.01]. Granisetron is more effective than metoclopramide in prevention of PONV after cataract surgery. Granisetron and dexamethasone are more effective than metoclopramide in prevention of late PONV after cataract surgery

3.
Journal of Mazandaran University of Medical Sciences. 2008; 18 (64): 22-28
in English | IMEMR | ID: emr-87983

ABSTRACT

The clinical and epidemiologic features of Kawasaki disease [KD] suggest an infectious etiology; however, the agent[s] remain unknown. Our purpose was to isolate the causative bacterial gene from peripheral blood leukocytes of patients with acute KD, by Universal polymerase chain reaction [UPCR], in Tehran Children's Medical Center. Universal polymerase chain reaction [UPCR] assay was used to amplify the bacterial 16S ribosomal RNA gene [rDNA]. Forty three [28 boys and 15 girls] were diagnosed with acute Kawasaki disease included in this study. The median age at diagnosis was 3.5 years [range: 0.5-9 years]. Twenty Nine [29] cases had typical KD criteria and 14 patients had atypical KD at diagnosis. Two of the 43 KD patients were positive for the Universal PCR assay for 16S rRNA, prior to intravenous g-globulin therapy [IVGT], while all specimens were negative by conventional blood culture. In our study, there was fever in 100%, conjunctivitis in 62.7%, rash in 83.72%, oral mucosal changes in 76.74%, peripheral changes in 37.20%, and cervical lymphadenopathy in 39.53% cases. The 16S rDNA sequence was positive in 4.65% of acute KD patients; this data shows that an infectious KD agent is traced in peripheral leukocytes. The question remains as to what true frequency of the16S rDNA sequence in KD is


Subject(s)
Humans , Male , Female , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/epidemiology , Genes, Bacterial , RNA, Ribosomal, 16S/isolation & purification , Leukocytes , Polymerase Chain Reaction
4.
KOOMESH-Journal of Semnan University of Medical Sciences. 2003; 5 (1, 2): 63-71
in Persian | IMEMR | ID: emr-63298

ABSTRACT

To evaluate the long-term immunity and immunologic memory provided by universal hepatitis B vaccination program at birth, and to evaluate the booster effects of different dosages of hepatitis B vaccine on children, who lost protective antibody titers to hepatitis B surface antigen [HBs -Ag], this study was conducted. Community-based sero-epidemiologic study was done on 453 healthy 10.5 years old Iranian children, one decade after implementation of a mass hepatitis B vaccination program. A booster vaccination with different dosages was given for children who did not have protective level of anti-hepatitis B surface antigen antibody [anti-HBs]. Quantitative serologic responses to different dosages of vaccine were compared using X[2] statistical test. A total of 42% children [191 of 453] children had low concentration [<10IU/L] of anti HBs antibody, 18.5% [84 of 453] were susceptible [antibody titer <2IU/L]. 87.2% of 165 nonprotected-boostered vaccines showed immunologic memory to different doses of booster, and developed protective antibody titer two weeks later. The differences between pre- [3.48 +/- 3.39; mean +/- SD] and post- [153 +/- 163.84] vaccination antibody titers were significant [p=0.000]. Antibody titers achieved by different doses of vaccine had significant proportion to vaccine doses. No hepatitis B infection markers were detected in those children who were not sero-protected and did not respond to booster dose of vaccination. According to these findings, universal hepatitis B vaccination program at birth provides adequate protection against hepatitis B virus infection at least for 10 years. It might suggest that booster vaccination is not recommended, but further follow-up studies at adulthood age group are recommended


Subject(s)
Humans , Follow-Up Studies , Immunologic Memory , Immunization, Secondary , Hepatitis B Antibodies/blood
SELECTION OF CITATIONS
SEARCH DETAIL